Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 694-700

  Wilking, Nils ^a,m   Lidbrink, E ^a   Wiklund, Tom ^b,p   Erikstein, Bjørn ^c,n   Lindman, Henrik ^d   Malmström, Per ^e   Kellokumpu Lehtinen, Pirkko ^f   Bengtsson, Nils Olof ^g   Söderlund, Gustaf ^h   Anker, Gun ⁱ   Wist, Erik ^j,ab   Ottosson, Susanne ^k   Salminen, Eeva ^l   Ljungman, Per ^m   Holte, Harald ⁿ   Nilsson, J ^o   Blomqvist, Carl ^p   Bergh, Jonas ^a,m   Höglund, Martin ^d   Bengtsson, Mats ^d   Gruber, Astrid ^m   Fornander, Tommy ^q   Petterson Sköld, Dagny ^r   Löfvenberg, Eva ^g   Villman, Kenneth ^s   Karlsson, Karin ^h   Hultborn, Ragnar ^t   Ottoson, Susanne ^t   Mattson, Jan ^t   Jansson, Svante ^t   Braide, Inger ^t   Carlsson, Göran ^t   Rödjer, Stig ^t   Sallerfors, Bengt ^e   Ahlgren, Johan ^u   Gawelin, Ann ^u   Sölderberg, Martin ^v   Hansen, Jörgen ^w   Stenstam, Britta ^x   Svensson, Jan Henry ^y   Norberg, Bengt ^z   Kvalheim, Gunnar ⁿ   Sommer, Hilde Heen ^j   Tangen, Jon Magnus ^j   Lundgren, Steinar ^aa   Remes, Kari ^l   Lehtinen, Marja ^ac   Koivinen, Elli ^ac   Turpeenniemi Hujanen, Taina ^ad   Kuittinen, Outi ^ad   Voutilainen, Leena ^ae   Mirza, Mansoor Raza ^af   Rose, Carsten ^af   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b Roche Oy   (Finland)

^c Southern Norway Regional Health Authority   (Norway)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k NÄL Hospital   (Sweden)

^l TURKU UNIVERSITY HOSPITAL   (Finland)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o Trial Form Support AB   (Sweden)

^p HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^q STOCKHOLM SÖDER HOSPITAL   (Sweden)

^r DANDERYD HOSPITAL   (Sweden)

^s ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^t SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^u GÄVLE HOSPITAL   (Sweden)

^v Karlstad Hospital   (Sweden)

^w Vasteras Hospital   (Sweden)

^x Västerås Hospital ^*  (Sweden)

^y BORÅS HOSPITAL   (Sweden)

^z RYHOV COUNTY HOSPITAL   (Sweden)

^aa TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^ab Regional Hospital   (Norway)

^ac TAMPERE UNIVERSITY HOSPITAL   (Finland)

^ad OULU UNIVERSITY HOSPITAL   (Finland)

^ae KUOPIO UNIVERSITY HOSPITAL   (Finland)

^af ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Adjuvant; Breast cancer; Randomised; Tailored chemotherapy

Indexed keywords

CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLEROXACIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34047161056     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl488     Document Type: Article

References (36)

1. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366: 2087-2106.
3. Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systemic review of published randomized trial involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460.
4. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611.
5. Fisher B, Anderson S, Wickerham D et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-1869.
6. Fisher B, Anderson S, DeCillis A et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17: 3374-3388.
7. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
8. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study [In Process Citation]. Lancet 2000; 356: 1384-1391.
9. Hanrahan EO, Broglio K, Frye D et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: Follow-up at 12 years. Cancer 2006; 106: 2327-2336.
10. Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005; 23: 2191-2200.
11. Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
12. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17-26.
13. Nitz UA, Mohrmann S, Fischer J et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 2005; 366: 1935-1944.
14. Leonard RC, Lind M, Twelves C et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial. J Natl Cancer Inst 2004; 96: 1076-1083.
15. Basser RL, O'Neill A, Martinelli G et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006; 24: 370-378.
16. Coombes RC, Howell A, Emson M et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: Long-term results of an international randomised trial. Ann Oncol 2005; 16: 726-734.
17. Roche H, Viens P, Biron P et al. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003; 10: 42-47.
18. Schrama JG, Faneyte IF, Schornagel JH et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up. Ann Oncol 2002; 13: 689-698.
19. Zander AR, Kroger N, Schmoor C et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 2004; 22: 2273-2283.
20. Hortobagyi GN, Buzdar AU, Theriault RL et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225-233.
21. Bearman S, Green S, Gralow J et al. SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with ≥4 involved axillary lymph nodes. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. J Clin Oncol 2005; 23: 21s (Abstr 572).
22. Rodenhuis S, Bontenbal M, van Hoesel QG et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006; 17: 588-596.
23. Tanner M, Isola J, Wiklund T et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/ neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2436.
24. Saarto T, Blomqvist C, Rissanen P et al. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997; 75: 301-305.
25. Poikonen P, Saarto T, Lundin J et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF [see comments]. Br J Cancer 1999; 80: 1763-1766.
26. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003; 89: 1837-1842.
27. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001; 91: 2246-2257.
28. Paridaens R, Wildiers J, Dumez H et al. Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): A retrospective analysis. 27th ESMO Congress, Nice. Ann of Oncol 2002; 13: 45 (Abstr 161).
29. Colleoni M, Pricer K, Catiglione-Gertsch M et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 1998; 34: 1693-1700.
30. Szutowicz E, Radecka B, Dziadziuszko R et al. Peripheral blood count nadirs during adjuvant CMF chemotherapy for breast cancer - lack of prognostic relevance: 3rd European Breast Cancer Conference, Barcelona. Eur J Cancer 2002; 38 (Suppl 3): S93 (Abstr 205).
31. Praga C, Bergh J, Bliss J et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23: 4179-4191.
32. Woo TC, Pignol JP, Rakovitch E et al. Body radiation exposure in breast cancer radiotherapy: Impact of breast IMRT and virtual wedge compensation techniques. Int J Radiat Oncol Biol Phys 2006; 65: 52-58.
33. Erselcan T, Kairemo KJ, Wiklund TA et al. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Br J Cancer 2000; 82: 777-781.
34. Hall KS, Wiklund T, Erikstein B et al. Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients. Breast Cancer Res Treat 2001; 67: 235-244.
35. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
36. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. New Engl J Med 2005; 352: 2302-2313.